Banner - NPPA Connect

All Videos

An expert discusses the shift in acne treatment from broad-spectrum antibiotics to targeted and nonantibiotic therapies, emphasizing microbiome preservation, resistance reduction, and personalized patient care.

1 expert in this video

An expert discusses how barzolvolimab demonstrated statistically significant and clinically meaningful reductions in UAS7 scores, with over 50% of patients achieving complete response and sustained disease control lasting 28 weeks after the final dose.

Panelists discuss how recent innovations like topical tapinarof and roflumilast are transforming plaque psoriasis treatment by offering nonsteroidal, effective, and well-tolerated options that modulate immune pathways for long-term management while noting the ongoing need for scalp-friendly formulations to improve usability and adherence in patients with scalp involvement.